跳至主要内容
临床试验/NL-OMON32256
NL-OMON32256尚未招募2 期

Prazosin for the treatment of Obsessive Compulsive Disorder: An open label, fixed dose add-on study. - Prazosin for therapy resistant OCD.

Academisch Medisch Centrum0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • DSM IV diagnosis obsessive-compulsive disorder
  • Y-BOCS score > 16
  • Therapy resistance (no response to at least 1 previous SRI treatment)
  • Male and female, aged 18-70 years
  • negative pregnancy test
  • Written informed consent

排除标准

  • Presence of major depression (HDRS>15), bipolar disorder, schizophrenia or any other psychotic condition, tic disorder, substance related disorder during the past 6 months, epilepsy, or any structural CNS disorder or stroke within the last year.
  • Evidence of clinically significant and unstable somatic abnormalities.
  • Patients at risk for suicide
  • Multiple serious drug allergies or known allergy for the trial compounds
  • Use of antipsychotics during 6 months before the screening visit
  • Use of any other psychotropic drug during 6 months before the screening visit
  • Cognitive and behavioural treatment 3 months prior to the screening visit
  • Use of drugs that interact with prazosin: diuretic, other antihypertensive agents, regular use of alcohol.

研究者

相似试验